Curenetics is a fast-evolving and advancing start-up, working hard to defeat cancer using medical technology. Cancer treatment varies from patient to patient and many cancer types now require immune-oncologic treatment or other forms of targeted therapy. How a patient responds to their treatment regime is not fully known which can result in patients suffering from unwanted side effects or developing potentially life-threatening immune-mediated toxicities. We are currently working towards developing cancer treatment response models using artificial intelligence. We aim to predict response to immuno-oncologic treatments in cancer patients by leveraging our platform’s capability to find features within a large array of asynchronous clinical and genomic data. We are identifying biomarkers that will predict response to immunotherapy, even before starting treatment. At the same time, Curenetics is also building a flagship AI model to match cancer patients to the right clinical trial, whatever stage of treatment you are in. Through our machine learning-driven algorithms, domain expertise, and ability to combine cancer molecular profiling data, we are giving patients hope by helping to recruit them to the most suitable clinical trials available. At the same time, supporting trial sponsors to meet their recruitment targets, saving costs, and reducing time to trial completion.